Baum, Joanna http://orcid.org/0000-0003-1938-0739
Zickler, Daniel
Bolbrinker, Juliane
Richter, Rolf
Braicu, Elena Ioana
Grabowski, Jacek
Sehouli, Jalid
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 25 November 2022
Accepted: 21 February 2023
First Online: 22 March 2023
Declarations
:
: Dr. med. LL.B. Joanna Baum (J. Baum)—Honorary: AstraZeneca. PD Dr. med. Daniel Zickler (D. Zickler)—Grant/Speaking fee: Baxter. PD Dr. med. Juliane Bolbrinker has no conflict of interest. Dr. rer. medic. Rolf Richter MPH (R. Richter) has no conflict of interest. Prof. Dr. med. Elena Ioana Braicu (E.I. Braicu)—Honorary: MSD, AstraZeneca, GSK, CLOVIS, RochePharma; consulting: MSD, AstraZeneca, GSK, CLOVIS, NOGGO; research funding: Bayer, MSD, Roche Diagnostic, and AstraZeneca. PD Dr. med. Jacek Grabowski (J.P. Grabowski)—Advisory, honoraria, speaker, travel-expenses: Tesaro/GSK, AstraZeneca, Clovis, Roche, Amgen, MSD, Pfizer, and Riemser. Prof. Dr. med. Dr. h. c. Jalid Sehouli (J. Sehouli)—Research funding: Roche Pharma, AstraZeneca, Bayer, Clovis, GlaxoSmith, Lilly, and Tesaro; Honorary: Tesaro, GlaxoSmith, PharmaMar, AstraZeneca, Clovis, Bayer, Roche PharmaMar, Vifor Pharma, Hexal AG, Novartis Pharma; consulting: Tesaro, Merck /Pfizer, PharmaMar, Clovis Oncology, AstraZeneca, Roche Pharma, GlaxoSmith, MSD, Eisai, Novocure, and Oncoinvent.